1050481-78-1 Usage
Description
(5-CHLORO-2-METHOXY-PHENYL)-ACETIC ACID ETHYL ESTER, with the molecular formula C10H11ClO3, is an ester derivative of (5-chloro-2-methoxyphenyl)acetic acid. It is a white to off-white solid with a slight odor and is soluble in organic solvents such as ethanol and acetone. This chemical compound is commonly used as an intermediate in the synthesis of pharmaceutical drugs and agrochemicals. Due to its potential to cause irritation to the skin, eyes, and respiratory system, it is important to handle this chemical with care.
Uses
Used in Pharmaceutical Industry:
(5-CHLORO-2-METHOXY-PHENYL)-ACETIC ACID ETHYL ESTER is used as an intermediate in the synthesis of pharmaceutical drugs for its ability to be incorporated into the molecular structure of various medications, contributing to their therapeutic effects.
Used in Agrochemical Industry:
(5-CHLORO-2-METHOXY-PHENYL)-ACETIC ACID ETHYL ESTER is used as an intermediate in the synthesis of agrochemicals for its role in creating compounds that can be utilized in the development of pesticides, herbicides, and other agricultural products to enhance crop protection and yield.
Check Digit Verification of cas no
The CAS Registry Mumber 1050481-78-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,0,4,8 and 1 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1050481-78:
(9*1)+(8*0)+(7*5)+(6*0)+(5*4)+(4*8)+(3*1)+(2*7)+(1*8)=121
121 % 10 = 1
So 1050481-78-1 is a valid CAS Registry Number.
1050481-78-1Relevant articles and documents
MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS
-
, (2021/11/26)
The present invention relates to the compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as maxi-K potassium channel openers, which makes them suitable for use in therapy, particularly in the treatment or prevention of fragile X associated disorders, such as fragile X syndrome.
